Optiver Holding’s Vir Biotechnology VIR Stock Holding History

Optiver Holding’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-456	Closed	-$2.6K	–	3034
2025 Q3	$2.6K	Buy	+456	New	+$2.33K	﹤0.01%	2263

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Optiver Holding's VIR Position: Q4 2025 in Review

Optiver Holding sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 456 shares — an estimated $2.6K sold.

Optiver Holding first reported a position in VIR in Q3 2025 and held it in 1 quarter. The position peaked at $2.6K in Q3 2025. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

Optiver Holding reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
Optiver Holding sold 456 Vir Biotechnology shares in Q4 2025, an estimated $2.6K.
Optiver Holding first reported a position in Vir Biotechnology in Q3 2025 and held it in 1 quarter.
Optiver Holding's Vir Biotechnology position peaked at $2.6K in Q3 2025.
218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Optiver Holding's 13F filing for Q4 2025, filed 17 Feb 2026.